Skip to main content
Clinical Trials/ISRCTN10994757
ISRCTN10994757
Completed
未知

A multi-centre, double-blind, randomised, controlled clinical trial of rifaximin to reduce infection in patients admitted to hospital with decompensated cirrhosis

Imperial College London0 sites78 target enrollmentMarch 8, 2017

Overview

Phase
未知
Intervention
Not specified
Conditions
Decompensated cirrhosis
Sponsor
Imperial College London
Enrollment
78
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

2021 Thesis results in https://doi.org/10.25560/97104 (added 30/08/2023)

Registry
who.int
Start Date
March 8, 2017
End Date
January 30, 2020
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • 1\. Clinical/biochemical/radiological \+/\- histological diagnosis of cirrhosis
  • 2\. Hospital admission with complication of cirrhosis (e.g. alcoholic hepatitis, sepsis, variceal bleeding)
  • 3\. Commencement on antimicrobial therapy
  • 4\. Aged 18 \- 80 years

Exclusion Criteria

  • 1\. C.difficile infection
  • 2\. HIV antibody positive
  • 3\. Immunosuppression (excluding low dose steroids/steroid sparing agents for AIH \<20 mg or equivalent of prednisolone)
  • 4\. Advanced disseminated Hepatocellular Carcinoma or invasive carcinoma
  • 5\. eGFR \< 30 on screening/randomisation
  • 6\. End\-stage/severe cardiac, pulmonary or kidney disease
  • 8\. Colitis or coeliac disease
  • 9\. Pregnancy
  • 10\. Already receiving rifamixin

Outcomes

Primary Outcomes

Not specified

Similar Trials